All participants got a link to register up for the workshops.
1) “The best science for the most neglected – how to achieve research & development for neglected diseases and diseases of poverty” Marcel Tanner (SwissTPH)
This workshop will provide the facts and figures on the still existing burden of neglected tropical diseases within the context of neglected health and social systems. Furthermore, Prof. Marcel Tanner will elaborate that neglected tropical diseases cannot be controlled or eliminated in the absence of new tools such as drugs, vaccines and dianostics. It will then be discussed how these challenges can be addressed through novel partnership approaches including the public and the private sector. Finally, the workshop ends with a potential “UAEM-declaration”.
2) “The Trans-Atlantic Trade Negotiations: Attacks on Access to Medicines & Clinical Research Data” Peter Maybarduk (Public Citizen)
Large pharmaceutical companies have articulated several key objectives for the negotiations underway between the European Union and United States. As a result, the “Trans-Atlantic Trade and Investment Partnership,” or T-TIP, may include provisions which assail European pharmaceutical pricing regulations, access to medicines in developing countries, and recent European efforts to require greater industry disclosure of clinical trial data, so that consumers can know more about the drugs we take. After a short introduction about trade agreements in general you’ll learn the latest about the T-TIP negotiations, and how we can work together to shift from defense to offense – from working to keep the rules from getting worse to growing our movement and developing global support for forward-thinking policies.
3) “The Medicines Patent Pool (MPP)” Ethan Guillen (MPP)
This workshop will give an overview of the Medicines Patent Pool. It will discuss MPP licenses as one model for voluntary licensing, and will highlight avenues for student advocacy with regards to voluntary licensing.
4) “Open Access to Data from Clinical Research on Essential Medicines” Erik von Elm (Cochrane) and Spring Gombe
Essential medicines need to have proven efficacy and safety in order to improve the health of people living in low- and middle-income countries. To date, much clinical research on drug treatments is conducted in the commercial sector and data derived from research involving patients (e.g. randomized trials) is not accessible to other researchers, health professionals, policy makers or patients. In the first part of the workshop, Erik von Elm, epidemiologist and co-director of Cochrane Switzerland, will discuss current initiatives to enable open access to clinical research data. Spring Gombe will, in the second part of the workshop, focus on initiatives to use this data for open source drug discovery. Examples will include the work of DNDi, the OSDD Initiative in India and Open Source Malaria. She will also present some of the most pressing ethical concerns arising from open access, open source and open knowledge initiatives.
5) “An insiders guide to WHO advocacy: on civil society’s role in the fight for access to medicines.” Thiru Balasubramaniam (KEI) and Elin Hoffmann Dahl (UAEM)
This workshop will focus on civil society’s past and future role in bringing access to medicines topics to the WHO arena. Participants will learn about the intricacies of Geneva campaigning and the status quo of access&innovation debates at WHO. We will then discuss potential avenues for involvement, both with regards to civil society in general, and UAEM in particular.
6) “Access to Medicines Advocacy in the EU Arena” Helle Aagaard (MSF Access Campaign)
This workshop will give an overview of current access challenges in the EU arena, and will introduce participants to “Brussels” advocacy. We will discuss how civil society can raise awareness for access&innovation at European institutions, building on previous successes and existing networks.
7) Socially Responsible Licensing: Bringing the Public Interest Back into University Tech Transfer” Harry Thangaraj (A2PP)
A significant amount of basic upstream research carried out through public funding is ultimately commercialised through the help of the private sector and result in essential goods including health technologies. Whose responsibility is it to ensure that the reach of these technologies extends to those who need it most, particularly the poor in developing countries? Can social goals be balanced against profit considerations. This talk deals with how intellectual property can be managed in a manner that benefits all.
8) “Menacing patent reforms – on the example of euphemisms like “Forward South Africa”” Céline Grillon (Act Up Paris) and Koichi Kameda (UAEM)
Intellectual Property (=patents) is controversely discussed, especially in emerging countries such as South Africa and Brazil. In this workshop you’ll learn more about the current patent reforms in these countries, after an introduction about some basic legal trade terms such as TRIPS and FTA. Céline Grillon and Koichi Kameda will furthermore discuss the role of the EU in this process, and point out possible avenues for advocacy regarding this situation.
9) “Consequences of profit-driven drug research” Patrick Durisch (EvB/HAI) and Eva Ombaka (HAI)
This workshop aims to elaborate different aspects (patents, access to medicines, R&D system, promotion of medicines) of our flawed profit-driven medical research system, with a special focus on the problem of offshoring drug trials. For strategic reasons but also to maximize profit, pharmaceutical companies are increasingly conducting trials offshore in developing countries, particularly emerging countries. All the big companies are involved, including the Swiss firms Roche, Novartis and Actelion. However, this “globalisation of clinical trials” entails frequent ethical violations due to the weak regulatory environments prevailing in many countries, the vulnerability of local populations and the profit-driven business model of Big Pharma. Strengthened ethical controls and more transparency at all levels are direly needed.
10) “Access to Medicines movement in South Africa” Linda Mafu (Global Fund)
Linda Mafu, grown up in South Africa, will provide participants with an insider overview of the Access to Medicines movement in her home country. Get inspired by her experience from the Treatment Action Campaign and learn about today’s state of play.
11) “Access to Medicines in Times of Economic Austerity” Vanessa Lopez (Salud por Derecho) and David Hammerstein (TACD)
This workshop will give an overview of current threats and trends in access to medicines. It will put a particular emphasis on intra-European access problems resulting from recent austerity politics. Together, we will explore how to raise awareness for alternative R&D mechanisms in the ongoing economic crisis.
12) “Setting the Scene for a New R&D System – what Role for Civil Society?” Rohit Malpani (MSF Access Campaign)
Our biomedical research system is deeply flawed. Participants will be provided with an overview of the different shortcomings of our R&D system, and discuss how Civil Society can play a part in fostering alternatives. One main focus will be the current movement for access to hepC medicines.
13) “How to start a Global Health-related professional career while keeping the fire glowing” Rachel Kiddell-Monroe (MSF/UAEM)
In this workshop, we will discuss ways to integrate UAEM ideals and goals into professional careers (both science and non-science). The workshop will aim to provide a platform for experience exchange, network-building and discussion.
14) “On the Road to an Equitable R&D Paradigm” Zafar Mirza (WHO)
In this workshop, Zafar Mirza will provide his perspective on the WHO’s process towards an enhanced global medical R&D system. Topics discussed will include an overview of how the WHO works, the CEWG process and the current state of play in WHO negotiations regarding R&D.
15) “DNDi’s concept of collaborative drug development. Past achievements and future challenges” Dominique Junod (DNDi)
This workshop will provide a general introduction to DNDi’s model of drug development. Based on participants’ interest, selected aspects can be explained in-depth (e.g., DNDi’s access policies in general or licensing strategies in particular).
16) “Access to Medicines – a Key to Global Health?” Albrecht Jahn (University of Heidelberg)
This workshop will provide insights into recent debates in global health and access to medicines. Albrecht Jahn will share experiences he made as a member of the WHO’s CEWG, and discuss recent political and academic trends and threats regarding access to medicines.
17) “Access to Treatment for Hepatitis C – The Next Frontier” Ellen ‘t Hoen
WHO recently published new treatment guidelines for HepatitisC. New antivirals that have come onto the market seem to be extremely effective in curing the disease. The drugs are also prohibitively expensive. This workshop will provide a briefing of basic facts of new HepC treatments, companies’ pricing of the new drugs and their licensing strategies so far. We will also discuss action steps and brainstorm about what UAEM and its members can undertake to assure access to new HepC treatments.
1) “Getting your chapter off the ground” Philipp Jaehn (UAEM Germany), Mila Johansen (UAEM Denmark), Julia Rappenecker (UAEM Global)
In this workshop, UAEM veterans will provide you with ideas on possible future projects for your newly created chapters. We’ll also share strategies of how to successfully recruit new motivated members. There will be time to exchange experiences regarding your specific chapter or country, and to discuss solutions to the problems you’re currently dealing with.
2) “Boost your campaigning skills – based on the example of Act Up Basel’s recent campaigns” Pauline Londeix and Cécile Cadu (Act Up Basel)
This workshop will offer you some very concrete campagning tools. Act up Basel conducted several campaigns in the field of Access to Medicines and will share their experience with you. Examples include “Indian Patent Law vs Novartis” and “Access to Hepatitis C vs Gilead”
3) “Building a broad de-linkage movement – how to involve our academics to change the current system?” Avgi Loizidou (UAEM UK) and Vanessa Lopez (Salud por Derecho)
Catalytic project (Salud por Derecho) and A&I breakfast project (UAEM): Two projects from two different organizations that want our Universities to take responsibility in the current de-linkage movement. Learn what they have planned, what they achieved so far and especially what YOU can do to make a step forward towards a global change.
4) “Evidence-based activism – the Drug Bio Project” Benjamin Ebeling (UAEM Denmark), Rosa Jahn (UAEM Germany) and Thiru Balasubramaniam (KEI)
Activism needs evidence. In this case, evidence to support UAEM’s claim about university research being a major contributor to medical research and development. This is exactly what the Drug Bio project will provide! We are looking at different drugs and writing their biographies – where do they come from and who developed them? We will introduce you to our research, our methodology and the challenges of finding information. We will work together to gain access to the information we need to advocate for access to medicines for all!
5) “Access to Medicine (A2M) week and Advocacy – Let’s kick start this!” Andrea Mauracher (UAEM CH) / Friha Aftab (UAEM Norway)
Interested in a European-wide movement that will push for Access to Medicines in every country UAEM is present in? For this workshop, we need inspired, passionate people, to really get to work on UAEM Europe’s (hopefully) biggest project yet! We’ll start you off with a bit of Advocacy Training. We will then jointly develop a list of specific activities that everyone can get involved in during “Access to Medicines Week”, so our vision of a united UAEM Europe becomes reality. WE KINDLY ASK AT LEAST ONE PERSON PER COUNTRY TO ATTEND THIS WORKSHOP!”
6) “Are We Wrong? An investigation into the strongest arguments against us.” Dzintars Gotham (UAEM UK)
“Patents aren’t really the problem – it’s all because of poverty.” “Intellectual Property protection is necessary to promote investment in poorer countries.” “Drug companies donate drugs to those who can’t afford them.” “Compulsory licenses are essentially theft.” This workshop will look at these claims and more, unpacking them and finding the best explanations for why they are wrong (or are they?).
7) “Writing with FEELING: Championing Access-to-Meds Topics through Op-Eds and other Media” Bryan Collinsworth (UAEM NA)
This workshop will give an introduction to persuasive writing in general, and Op-Ed writing in particular. We will analyze a few particularly nice examples of previous Op-Eds by UAEMers that got published, to get a feel for successful structures and techniques. Elements discussed will include choosing an effective angle & scope, crafting a message, and interaction with press / getting something published. The workshop will build on the experience of defending and promoting UAEM’s agenda in North America.
8) “Designing an advocacy campaign in Switzerland: the example of unethical drug trials” Patrick Durisch (EvB / HAI)
This interactive session will guide participants through the different methodological steps of designing a campaign in the Swiss context. It will highlight some important lessons learnt, based on the example of the Berne Declaration’s recent campaign on unethical drug trials.
9) “Knowing the Big Picture – One Health: an Integrative Health Risk Management Perspective” Walter Ammann (Global Risk Forum / One Health)
Many emerging health issues are linked to increasing contact between humans and animals, the industrialization of food production, and environmental pollution. These complex interactions impacting human health need integrative approaches to cope with. A promising approach is the “One Health” concept, which frames the complex interactions between human health, livestock, pet and wildlife health, ecosystems health, climate, agriculture, food systems, water and sanitation, and human development. Mitigating the impacts from threats like emerging pathogens, toxicant releases, climate change, and changes in the built environment requires pooling of global public health resources and capabilities across multiple disciplines. For example: According to WHO, 60% of the neglected infectious disease pathogens of humans are zoonotic. To address this group of diseases, cross-sectoral efforts of human and animal health systems are essential. The aim of this Workshop is to introduce the “One Health” concept and to identify UAEM’s role in this multidisciplinary network to find mutual approaches, which may lead to collaborative projects in the future.
10) “Building an Effective Campaign: Lessons from the UCL experience” Anelise Rosa (UAEM UK) and Gloria Tavera (UAEM NA)
Following three years of passionate efforts by the local UAEM chapter, UCL in London recently became the largest European university (by research output) to adopt a socially responsible licensing policy. We’ve since had a chance to reflect on our campaigning strategies and would like to share what we’ve learnt with other chapters. Join us for an interactive discussion of the problems currently facing UAEM chapters and how they can be resolved.
11) “Energizing your local chapter” Lukas Fendel (UAEM Europe) and a team of experienced UAEMers
For successful campus campaigning, UAEM depends on lively and sustainable local chapters. This workshop will highlight several elements of successful chapter work. The exact contents of the workshop will be taylored to interest and needs “on the go”, which will permit participants to experience a participatory and needs-based approach to group learning. Possible topics include strategy and action planning, recruitment techniques, avant-garde formats for chapter meetings, and moderation techniques.